SCHEMBL19781537

SCHEMBL19781537

CC(C)Oc1ccc(-c2cc3c(cn2)ncn3-c2ccc(OC(C)C)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.55
FGFR1 P11362 5/20 0.55
KDR P35968 1/20 0.44
HTT P42858 4/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
MAPK10 P53779 1/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
CYP11B2 P19099 1/20 0.40
CYP1A2 P05177 1/20 0.40
MCHR1 Q99705 1/20 0.40
GSK3B P49841 1/20 0.39
KDM4E B2RXH2 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
PTK2B Q14289 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19781506 0.90 FGFR1 (0.49) KCNH2FGFR1ALDH1A1MAPTHPGD
SCHEMBL19781604 0.90 KCNH2 (0.48) KCNH2FGFR1KDRHTTALDH1A1
SCHEMBL21449942 0.86 GABRP (0.49) KCNH2FGFR1KDRHTTALDH1A1
SCHEMBL29636286 0.83 FGFR1 (0.56) KCNH2FGFR1KDRHTTALDH1A1
SCHEMBL19781595 0.83 FGFR1 (0.56) KCNH2FGFR1KDRHTTALDH1A1
SCHEMBL19781511 0.83 FGFR1 (0.59) FGFR1KDRHTTALDH1A1MAPT
SCHEMBL19781575 0.79 FGFR1 (0.57) KCNH2FGFR1KDRHTTALDH1A1
SCHEMBL19781598 0.77 FGFR1 (0.55) KCNH2FGFR1KDRHTTALDH1A1
SCHEMBL19781251 0.76 FGFR1 (0.58) KCNH2FGFR1KDRHTTALDH1A1
SCHEMBL19781569 0.76 FGFR1 (0.51) FGFR1KDRHTTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
WO-2018013430-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S KCNH2 107/4885FGFR1 3928/4885KDR 3283/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S KCNH2 107/4885FGFR1 3928/4885KDR 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.